At the core of Hyper-C are Delta4's proprietary, expertly curated catalogs and ontologies. These structured vocabularies connect molecular features, phenotypes, drugs, biological mechanisms, and tissue or cell-type data thus forming the foundation that powers our platform's precision and discovery capabilities.
Delta4's proprietary literature-mining LLM-RAG pipeline converts unstructured scientific text into structured data, uncovering and linking key biological entities within our Hyper-KG knowledge graph.
Delta4's Hyper-KG is an advanced biomedical knowledge graph that unifies diverse and complex data into a single, connected framework. It forms the foundation for our graph-based machine learning, molecular model generation, and ontology-driven reasoning thus enabling the discovery of hidden relationships between diseases, drugs, targets, and biomarkers.
Delta4's context-dependent human interactome integrates experimentally validated and computationally inferred protein–protein interactions, creating a comprehensive framework that powers the generation of accurate molecular models of disease and drug mechanism of action.
At the heart of the Hyper-C platform lies Delta4's proprietary collection of context-dependent molecular models of disease pathobiology and drug mechanism of action. This unique foundation powers Delta4's drug discovery, target prioritization, and biomarker identification efforts.
Delta4's proprietary, scientifically validated workflow connects disease biology with drug mechanisms of action using advanced network biology and graph theory. This unique approach uncovers novel opportunities for drug discovery and develops innovative treatment options for human diseases.
Combo-C is Delta4's AI-powered software platform designed to systematically identify and evaluate effective drug combinations for human diseases. It leverages Delta4's proprietary network-based disease pathobiology models and drug mechanism of action insights to accelerate discovery and optimize therapeutic outcomes.
Delta4's Hyper-C platform integrates diverse biomedical data to deliver powerful scoring schemes for biomarker and drug target identification. By combining molecular disease models with drug mechanism of action insights, we enable precise selection and prioritization of biomarkers and therapeutic targets across human diseases.